Application of pcdh11x mutation in predicting sensitivity to immune checkpoint inhibitor therapy in patients with non-small cell lung cancer

1. PCDH11X, non-small cell lung cancer technology, applied in the direction of microbial determination/inspection, measuring devices, biochemical equipment and methods, etc., can solve the problems of lack of detection methods
CN113355424BActive Publication Date: 2022-03-25SIMCERE DIAGNOSTICS CO LTD +2
4 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
SIMCERE DIAGNOSTICS CO LTD
Publication Date
2022-03-25

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The present invention relates to the role of PCDH11X mutations in predicting the sensitivity of non-small cell lung cancer patients to immune checkpoint inhibitor therapy, as well as in predicting tumor mutation load, DNA mismatch repair pathway gene mutations, and the degree of immune cell infiltration in tumors in patients with non-small cell lung cancer application.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to the field of molecular diagnosis, in particular to the application of PCDH11X mutation in predicting the sensitivity of non-small cell lung cancer patients to immune checkpoint inhibitor therapy. Background technique

[0002] In recent years, treatments based on PD-1 / PD-L1, CTLA-4 and other emerging immune checkpoint inhibitors (Immune checkpoint inhibitors, ICIs) have been widely studied in various solid tumors, and have entered non-small cell lung cancer. (NSCLC) first-line treatment. Although the effect of immune checkpoint inhibitors is good, the overall objective response rate (ORR) is still only about 20%. Therefore, the development of suitable biomarkers to accurately screen more patients who benefit from immunotherapy is an urgent problem to be solved in the future development of tumor immunotherapy The key issue.

[0003] Detection of tumor PD-L1 expression based on immunohistochemical staining is currently the most ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More